AstraZeneca has revealed plans to directly list its shares on the New York Stock Exchange beginning February 2, 2026, while maintaining its presence in London and Stockholm. This initiative, driven by the company's U.S. operations that accounted for 43% of its total revenue last year, includes a commitment to invest $50 billion in U.S. manufacturing by 2030. However, the company faces challenges, including a halted £200 million investment in its Cambridge site and pressure to reduce drug prices for U.S. patients.
“AstraZeneca · plans to offer its shares directly on · the New York Stock Exchange · from next February”
“AstraZeneca · retains its listings in · London and Stockholm · true”
“AstraZeneca · U.S. business accounted for · 43% of total revenue last year · true”
“U.S. shareholders · represent · AstraZeneca's largest single investor group · true”
“AstraZeneca · has no current plans to scrap · its London listing · true”
“22.5% of AstraZeneca's shareholders · are based in · North America · true”
“AstraZeneca · has a market capitalisation of · $230 billion · as of Monday's close”
“AstraZeneca · has faced calls from investors to shift its listing · similar to other companies · true”
“AstraZeneca's decision · signals · clear confidence in the UK economy · true”
“AstraZeneca · may make a full exit in future · from the UK market · true”
“Astrazeneca · has returned · year-to-date performance · 13.1%”
“Astrazeneca · has a · Zacks Rank · #2 (Buy)”
.jpeg&width=160)
